ClinicalTrials.gg
RecruitingNCT07350837Updated Apr 16, 2026

CAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant Participants

An Early Phase 1 interventional study of AZD0120 in Highly Sensitized Patients Awaiting Kidney Transplant, sponsored by Tongji Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Tongji Hospital · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 114 studies in Kidney Failure, Chronic with a site in China — 28 open to participants now, 36 under way, 1 of them phase 3. Kidney Failure, Chronic · China.

Planned enrollment
81st of 83
12 · median 150
Started
2026
with 5 others
Phase 1
6 of 114
2 open now
Primary completion
2026-12
later than 20 of 35 live
Registered
103rd of 114
by date

Among the 114 studies in Kidney Failure, Chronic with a site in China, this one is the 81st largest by planned enrollment of the 83 interventional ones that give a count, is one of 6 that started in 2026, is one of 6 in phase 1, reaches primary completion later than 20 of the 35 other live ones, and was the 103rd registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

28 of the 114 studies in Kidney Failure, Chronic with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Kidney Failure, Chronic with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability, and efficacy of AZD0120 in highly sensitized adult participants with ESKD awaiting kidney transplant-who, as assessed by investigators, are improbable desensitization through conventional treatments (e.g., plasmapheresis and immunoadsorption)- with or without living donors.

Read the detailed description

This is a single-arm, open-label, early-phase clinical study of AZD0120, a dual-directed CD19/BCMA CAR-T therapy in highly sensitized adult participants with ESKD awaiting kidney transplant. This study aims to evaluate the safety, tolerability, and efficacy of AZD0120 in highly sensitized adult participants with end-stage kidney disease (ESKD) awaiting kidney transplantation-who, as assessed by investigators, are improbable desensitization through conventional treatments (e.g., plasmapheresis and immunoadsorption)-with the participants divided into Cohort 1 (with living donors) and Cohort 2 (without living donors).

03

Conditions studied

  • Highly Sensitized Patients Awaiting Kidney Transplant

Keywords

  • Investigator-Initiated Trial
  • End-stage kidney disease
  • Dual directed CD19/BCMA CAR-T desensitization therapy
  • Kidney Transplantation
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Adult men or women aged 18 to 65 years with end-stage kidney disease who are waiting for kidney transplant and require desensitization to enable safe kidney transplant.

    2. Cohort 1:

  • A living donor who meets criteria for kidney donation based on national and local center-specific guidelines has been identified
  • Highly sensitized participants with a requirement of positive flow cytometry crossmatch, resulting from at least one DSA detected using Luminex SAB during or before Screening
  • A positive virtual crossmatch, using Luminex SAB (MFI ≥ 2000), obtained within 30 days of Screening and during Screening

Cohort 2:

  • PRA greater than or equal to 80% which is consistent with highly sensitized based on national criteria
  • At least one anti-HLA antibody that is unacceptable for kidney transplantation 3. High-resolution HLA typing for both the recipient and the donor within 2 years of Screening.

    4. The participant is currently eligible for transplantation according to local standards if a graft becomes available upon completion of treatment with the study intervention.

    5. ≥ 8 g/dL. 6. ≥ 800/μL. 7. Absolute lymphocyte count ≥ 2000/μL or CD3 T cell count ≥ 500/μL. 8. count ≥ 75000/μL. 9. Vaccinations must be up to date in accordance with the national and local center guidance for transplant participants.

    10. Positive for EBV capsid IgG. 11. Testing for latent TB infection must be negative within 3 months prior to Screening. Testing should be conducted using either a purified protein derivative or an IFN-γ release assay (ie, QuantiFERON-TB or T-SPOT.TB). Participants with a positive test for latent TB infection must complete appropriate therapy for LTBI.

A participant is considered eligible if he/she has a negative test for LTBI within 3 months prior to Screening, or if he/she has completed appropriate LTBI therapy prior to transplantation. Treatment for latent TB infection should follow national guidelines.

12. Participants must be willing to be hospitalized for at least 2 weeks from the time of AZD0120 infusion and must reside within 2 hours of the hospital for an additional 2 weeks following hospital discharge.

13. Capable of giving signed which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

14. use by male and female participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

15. Nonsterilized male participants who are sexually active with female partner of (See Appendix D for details):

(a)Must agree to use one highly effective method of birth control for at least 3 years post AZD0120 infusion.

(b)For participants who receive LDC but not AZD0120, the contraception time lasts from enrollment until 6 months after the last dose of LDC.

(c)Must refrain from fathering a child or donating sperm within 3 years post AZD0120 infusion.

(d)Female partner of a male participant must use one highly effective method of birth control for at least 3 years post AZD0120 infusion.

16. Female participants (See Appendix D for details):

  1. FOCBP who are sexually active with a non-sterilized male partner must agree to use one highly effective method of birth control for at least 3 years post AZD0120 infusion. For FOCBP participants who receive LDC but not AZD0120, the contraception time lasts from enrollment until 12 months after the last dose of LDC. Cessation of contraception after this point should be discussed with a responsible physician.
  2. All FOCBP must have a negative serum pregnancy test result 3 days prior to enrollment at Screening.
  3. Must refrain from donating ova within 3 years post AZD0120 infusion.

Exclusion criteria

Exclusion Criteria:

  • 1. Previous solid organ (except kidney) or bone marrow transplant. 2. Complement 3 glomerulopathy, immune-complex mediated membranoproliferative glomerulonephritis, or focal and segmental glomerulosclerosis as the cause of ESKD in the native kidney.

    3. Severe peripheral arterial disease is defined by the presence of resting pain and/or non healing skin ulcers.

    4. History of recurrent UTI; 2 in 6 months or 3 in one year. 5. Active invasive bacterial, viral or fungal infection. Additionally, any infection requiring hospitalization and IV antibiotics within 4 weeks of Screening or PO antibiotics within 2 weeks.

    6. History of regardless of treatment. 7. Evidence of active infection based on positive HBsAg or positive core antibody (anti HBc): participants with positive anti-HBc but negative HBsAg may be enrolled if the HBV DNA test result is negative during the Screening Period.

    8. Evidence of active infection - Positive HCV antibody: Participants with positive HCV antibody and negative HCV RNA test during the Screening Period and absence of cirrhosis may be enrolled.

    9. Detectable viral load for CMV, EBV, BKV or SARS-CoV-2, as determined by PCR. 10. CMV serology incompatible with donor (eg, a recipient with a CMV negative serology should not receive an organ from a CMV positive donor).

    11. History of cirrhosis or severe liver disease, including abnormal liver profile (, ALT, or total > 3 × at Screening, except for participants whose hyperbilirubinemia is attributed to Gilbert's syndrome).

    12. History of sickle cell disease or systemic amyloidosis. 13. Any chronic illness requiring uninterrupted anticoagulation or antiplatelet therapy, except for clinical stable and asymptomatic conditions (eg, chronic atrial fibrillation).

    14. Active and severe disease requiring prolonged therapy, except for low dose (prednisone or prednisone equivalent \< 10 mg/day).

    15. Receiving ongoing immunosuppressive treatment, including corticosteroids (excepting \< 10 mg/d of prednisone or prednisone equivalent), IV immunoglobulin, CYC, mycophenolic acid, or azathioprine, from 90 days prior to Screening.

    16. CNI use within 14 days prior to Screening. 17. Any B cell depleting or monoclonal antibody therapy within 6 months prior to enrollment.

    18. Cardiac clearance for transplant > 6 months old and/or any of the following conditions: Class III or IV heart failure, unstable angina, \< 40%, a history of recent (within 6 months of Screening) myocardial infarction or presence of implantable cardioverter/defibrillators and/or biventricular pacing.

    19. Moderate-severe pulmonary function abnormality, defined as resting oxygen saturation \< 92% on room air or , total lung capacity, or DLCO (after correction for ) \< 50% of predicted values within 6 months of Screening.

    20. Known life-threatening allergies, , or intolerance to AZD0120 or its , including DMSO.

    21. Pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 3 years after receiving study intervention.

    22. Plans to father a child while enrolled in this study or within 3 years after receiving study intervention.

Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    AZD0120 CAR-T Cell Injection

    This study is An Early Exploratory. The main purpose is an IIT clinical trial to evaluate the safety, tolerability, and efficacy of AZD0120 in highly sensitized adult participants with ESKD awaiting kidney transplant.

    Drug: AZD0120

Interventions

06

What researchers measure

Primary outcomes

  1. The incidence of treatment-related adverse events AE/SAE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.A SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed:Results in death and life-threatening.

    Time frame: Through study completion, an average of 3 years

  2. Occurrence of DLTs.

    Dose toxicity is defined as any TEAE that meets the following criteria which cannot be attributed to the disease under study. Dose toxicity will be evaluated according to the ASTCT criteria, and the NCI CTCAE Version 5.0.

    Time frame: Through study completion, an average of 3 years

Secondary outcomes

  1. Assessment of CAR transgene levels of AZD0120 in peripheral blood over time by ddPCR.

    CK CAR transgene levels by ddPCR

    Time frame: Through study completion, an average of 3 years

  2. Maximum plasma concentration (Cmax)

    Cytokinetics (CK) profile of AZD0120 CAR-T celltherapy

    Time frame: Through study completion, an average of 3 years

  3. Time to maximum plasma concentration (Tmax)

    Cytokinetics (CK) profile of AZD0120 CAR-T celltherapy

    Time frame: Through study completion, an average of 3 years

  4. Last detectable time point(AUC0-28d)

    Cytokinetics (CK) profile of AZD0120 CAR-T celltherapy

    Time frame: Through study completion, an average of 3 years

  5. Last detectable time point(Tlast)

    Cytokinetics (CK) profile of AZD0120 CAR-T celltherapy

    Time frame: Through study completion, an average of 3 years

  6. Last quantifiable concentratione (Clast)

    Cytokinetics (CK) profile of AZD0120 CAR-T celltherapy

    Time frame: Through study completion, an average of 3 years

  7. Circulating soluble BCMA protein levels

    Blood will be collected for the measurement of the pharmacodynamics parameters

    Time frame: Through study completion, an average of 3 years

  8. Depletion of BCMA-expressing B cells

    Blood will be collected for the measurement of the pharmacodynamics parameters

    Time frame: Through study completion, an average of 3 years

  9. Depletion of CD19-expressing B cells

    Blood will be collected for the measurement of the pharmacodynamics parameters

    Time frame: Through study completion, an average of 3 years

  10. Lymphocyte subsets

    To evaluate immune cell and signaling responses in peripheral blood after AZD0120 infusion

    Time frame: Through study completion, an average of 3 years

  11. Time to recovery of lymphocytes and B cells to baseline

    To evaluate immune cell and signaling responses in peripheral blood after AZD0120 infusion

    Time frame: Through study completion, an average of 3 years

  12. Levels of cytokine in peripheral blood IL1, IL2, IL4, IL6, IL8, IL10, IL12, IL13, IFN-γ, and TNF-α

    To evaluate immune cell and signaling responses in peripheral blood after AZD0120 infusion

    Time frame: Through study completion, an average of 3 years

  13. Change from baseline in serum immunoglobulin concentration (including IgG, IgM, IgA, and IgE and IgG subclasses 1-4)

    To evaluate immune cell and signaling responses in peripheral blood after AZD0120 infusion

    Time frame: Through study completion, an average of 3 years

  14. Time to nadir and recovery of IgG

    To evaluate immune cell and signaling responses in peripheral blood after AZD0120 infusion

    Time frame: Through study completion, an average of 3 years

  15. Change from baseline in vaccination titers for MMR(measles, mumps, and rubella (vaccine))

    To measure pharmacodynamics parameters

    Time frame: Through study completion, an average of 3 years

  16. Change from baseline in vaccination titers for VZV(varicellazoster virus)

    To measure pharmacodynamics parameters

    Time frame: Through study completion, an average of 3 years

  17. Change from baseline in vaccination titers for Tetanus

    To measure pharmacodynamics parameters

    Time frame: Through study completion, an average of 3 years

  18. Change from baseline in vaccination titers for HBV

    To measure pharmacodynamics parameters

    Time frame: Through study completion, an average of 3 years

  19. Flow cytometry for CD19 (pan B cell marker), CD20 (pan B cell marker), CD138 (plasma cells), CD23 (follicular dendritic cells), CD3 (T cells), BCMA (plasma cells), and CD68 (macrophages)

    To evaluate cell composition in the lymphatic tissues after AZD01210 infusion in participants who receive kidney transplant.

    Time frame: Through study completion, an average of 3 years

  20. The incidence of anti CAR AZD0120 antibody response through the duration of the study

    To evaluate immunogenicity of AZD0120

    Time frame: Through study completion, an average of 3 years

  21. The incidence of anti CAR AZD0120 antibody titer through the duration of the study

    To evaluate immunogenicity of AZD0120

    Time frame: Through study completion, an average of 3 years

  22. The incidence of anti CAR AZD0120 antibody category of response through the duration of the study

    To evaluate immunogenicity of AZD0120

    Time frame: Through study completion, an average of 3 years

  23. Proportion of participants who achieve a negative virtual crossmatch based on anti-HLA antibodies Luminex assay

    To evaluate the clinical efficacy of AZD0120 in reducing DSA and improving HLA compatibility

    Time frame: Through study completion, an average of 3 years

  24. Proportion of participants who achieve a negative flow cytometry crossmatch

    To evaluate the clinical efficacy of AZD0120 in reducing DSA and improving HLA compatibility

    Time frame: Through study completion, an average of 3 years

  25. Proportion of participants who achieve a negative CDC crossmatch

    To evaluate the clinical efficacy of AZD0120 in reducing DSA and improving HLA compatibility

    Time frame: Through study completion, an average of 3 years

  26. Percentage and absolute decrease in MFI of Class I and II anti HLA antibodies from baseline to transplantation or the end of follow-up

    To evaluate the clinical efficacy of AZD0120 in reducing DSA and improving HLA compatibility

    Time frame: Through study completion, an average of 3 years

  27. Decline in MFI of Class I and II anti HLA antibodies to MFI < 2000, < 3000, < 5000.

    To evaluate the clinical efficacy of AZD0120 in reducing DSA and improving HLA compatibility

    Time frame: Through study completion, an average of 3 years

  28. Number and proportion of anti HLA antibodies unacceptable for kidney transplantation that were removed.

    To evaluate the clinical efficacy of AZD0120 in reducing DSA and improving HLA compatibility

    Time frame: Through study completion, an average of 3 years

  29. Number and proportion of DSAs removed

    To evaluate the clinical efficacy of AZD0120 in reducing DSA and improving HLA compatibility

    Time frame: Through study completion, an average of 3 years

  30. Proportion of participants achieving ≥ doubling of donor availability based on national PRA.

    To evaluate the clinical efficacy of AZD0120 in reducing DSA and improving HLA compatibility

    Time frame: Through study completion, an average of 3 years

  31. Change in national PRA from baseline over time until kidney transplantation or the end of follow-up, with and without serial dilutions.

    To evaluate the clinical efficacy of AZD0120 in reducing DSA and improving HLA compatibility

    Time frame: Through study completion, an average of 3 years

  32. Time to anti-HLA antibody nadir.

    To evaluate the clinical efficacy of AZD0120 in reducing DSA and improving HLA compatibility

    Time frame: Through study completion, an average of 3 years

07

Study locations

1 of 1 sites recruiting
  • Tongji Hospital, Tongji Medical Collage of Huazhong University of Science & Technology
    Wuhan, Hubei, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Of 67 phase 1 interventional studies under Kidney Failure, Chronic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's planned 11 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2025
First posted
Jan 20, 2026
StartActual
Jan 28, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2029
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07350837
Lead sponsor
Tongji Hospital
Responsible party
Gang Chen (Ph.D, Tongji Hospital) — Principal investigator
First posted
Jan 20, 2026
Start date
Jan 28, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Apr 16, 2026

Study contacts

Gang Chen
Contact
gchen@tjh.tjmu.edu.cn
027-83662892
Gang Chen
principal investigator · Tongji Hospital, Tongji Medical Collage of Huazhong University of Science & Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F

Start the discussion